News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Conference News AHA 2022 New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events Yael L. Maxwell November 07, 2022
News Conference News AHA 2022 Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock Caitlin E. Cox November 06, 2022
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 Remission, Not Cure: No Weaning Off Meds for Dilated Cardiomyopathy Patients, Says TRED-HF Shelley Wood November 11, 2018
News Conference News AHA 2018 PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure Michael O'Riordan November 11, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018